For most of the last fifty years, mainstream pharmaceutical companies did not touch psychedelics. In the past three years, they have committed billions of dollars to them. Understanding why is less about ideology and more about a specific alignment of commercial precedent, late-stage clinical data, and unmet medical need.

The Anchor: J&J's Spravato

Johnson & Johnson's Spravato (esketamine), an intranasal S-enantiomer of ketamine, was approved by the FDA in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) requiring in-clinic administration and observation. It was the first meaningfully novel mechanism approved for depression in decades. Its commercial performance — approximately $468 million in first-quarter 2026 sales — quietly settled the commercial question the psychedelic category needed answered: yes, a controlled-substance, in-clinic, REMS-restricted psychiatric therapy can generate serious revenue.

Ketamine and esketamine are dissociative anesthetics, not classic serotonergic psychedelics. But from a pharmaceutical-commercial standpoint, they proved the operating model that classic psychedelics would need: schedule-controlled compound, in-clinic supervised administration, distinct billing pathway, real physician adoption.

The Signal: Lilly / AtaiBeckley

On July 16, 2026, Eli Lilly announced the acquisition of AtaiBeckley for up to approximately $3.8 billion. The lead asset is BPL-003, a synthetic 5-MeO-DMT intranasal formulation with FDA Breakthrough Therapy Designation and Phase 3 status for treatment-resistant depression. Full detail in our Lilly acquisition piece. It is the largest pharmaceutical acquisition to date focused on a psychedelic asset — a threshold-crossing event that formally re-priced the category.

SSRI medications are not always the answer — psychedelic therapy alternatives and FDA clinical trial findings at Sanctuary Tulum
FDA Clinical Research —

The Pipeline: COMPASS, MAPS/Lykos, Usona

COMPASS Pathways has been running a Phase 3 program of COMP360 (synthetic psilocybin) for treatment-resistant depression, following Breakthrough Therapy Designation in 2018 and positive Phase 2b data showing significant response at three weeks after a single 25 mg dose (see our psilocybin trials piece). Usona Institute holds Breakthrough Therapy Designation for psilocybin in major depressive disorder. Lykos Therapeutics (formerly MAPS PBC) is developing another Phase 3 trial of MDMA-assisted therapy for PTSD following the FDA's Complete Response Letter in August 2024 (detail in our MDMA trials piece).

Bufo 5-MeO-DMT ceremony at Sanctuary Tulum — licensed, medically supervised, private one-on-one psychedelic ceremonies
Bufo 5-MeO-DMT Ceremony —

The Underlying Demand

The commercial thesis rests on real clinical unmet need. Roughly a third of people diagnosed with major depressive disorder do not achieve remission with standard antidepressant regimens (see the STAR*D program data). PTSD outcomes with existing first-line treatments — SSRIs and trauma-focused psychotherapies — leave a large residual-symptom population. Neither depression nor PTSD has seen a truly novel mechanism approved in the past several decades outside of esketamine. That is what a market looks like from a drug developer's perspective.

Capital committed is not the same as clinical benefit delivered. What the pharmaceutical pipeline validates is the mechanism — not the setting, the preparation, or the integration work that determines whether a person actually heals.Sanctuary Tulum Clinical Team —

Why the Operating Model Changed the Calculus

Historically, one of the pharmaceutical industry's objections to psychedelic drug development was operational: how would you actually distribute and administer a controlled-substance therapy that required hours of supervised in-clinic time? Spravato answered that question empirically. J&J built a REMS-restricted clinic network, established payer coverage pathways with commercial and Medicare plans, and demonstrated that specialty pharmacies and provider-administered billing codes could support the model at scale. Every psychedelic program that follows now inherits that template rather than having to invent it from scratch — a large hidden cost that has been removed from the category's business case.

Medically Supervised Ceremonies

What Investment Does Not Prove

Pharma capital is a signal of institutional expectation, not scientific certainty. Multiple well-funded programs have failed in Phase 3 across psychiatry over the past decade. The MDMA CRL is the clearest recent example that a compound can carry Breakthrough Therapy Designation, produce statistically significant Phase 3 results, and still not clear the FDA. The correct reading of the current moment is: the field has crossed from fringe to legitimate mainstream drug development, and the next several years will determine which specific compounds actually make it through.

What to Watch Next

The near-term inflection points are: (1) COMPASS Pathways Phase 3 psilocybin readouts and any subsequent NDA filing; (2) Lykos's redesigned MDMA Phase 3 trial and its endpoint choices; (3) BPL-003 Phase 3 progress inside Lilly's development machinery; and (4) DEA scheduling action — or absence of it — on any specific formulation the FDA does approve. Watching those four milestones is a more informative way to read the field than watching headlines about broader "psychedelic momentum," which will move on sentiment regardless of what the trials actually show.

The Payer and Coverage Question

One question that has to be answered separately from FDA approval is whether commercial and government payers will cover a supervised, in-clinic psychedelic therapy at a price that supports the operating model. Spravato's coverage arc is instructive: initial payer pushback, followed by gradual expansion of coverage as real-world outcome data accumulated and treatment-resistant depression prior-authorization pathways were built. A hypothetical FDA-approved psilocybin or MDMA therapy would have to run a similar arc, likely with a slower ramp given the longer per-session time requirements. The commercial thesis assumes payers eventually cover; the timing and rate of that coverage will materially affect any near-term revenue estimate.

The Legitimacy Effect

Beyond the specific programs, the pharma capital committed to the category has a second-order effect: it moves the surrounding conversation about psychedelic medicine into more mainstream forums. Regulatory agencies, medical societies, insurers, hospital systems, and academic training programs all engage differently with a therapy area that has committed institutional capital behind it than with one that remains speculative. That legitimacy is neither proof nor refutation of clinical efficacy — the trials determine that — but it changes the operating environment in which clinical claims are evaluated, and it is one of the reasons the next decade of psychedelic medicine will look qualitatively different from the last five.

Where the Capital Actually Went

The Eli Lilly / AtaiBeckley transaction dominates the headline dollars, but the broader capital picture includes: J&J's continued commercial investment behind Spravato's clinic network and payer coverage; COMPASS Pathways' late-stage program funding; Usona Institute's not-for-profit development of psilocybin for major depressive disorder; and the venture capital that has flowed into second- and third-tier psychedelic biotechs over the past five years (Cybin, GH Research, Delix, and others). Not all of that capital will produce approved products, but the total commitment is now at a scale that supports the infrastructure — trial sites, therapist training programs, manufacturing capacity — that the category needs to function as a legitimate pharmaceutical class.

A Note on Sanctuary Tulum

None of the psychedelic compounds above are currently FDA-approved for psychiatric indications in the United States. Sanctuary Tulum operates in Tulum, Mexico under Mexico's federal health authority federal health license and has worked with ayahuasca, ibogaine, 5-MeO-DMT, and psilocybin in a licensed, physician-supervised setting since 2011.

References